These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 22870740

  • 1. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
    Cetin M, Uçar O, Cicekçioğlu H, Güven Cetin Z, Sahin M, Vasfi Ulusoy F, Aydoğdu S.
    Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
    [Abstract] [Full Text] [Related]

  • 2. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E, Erturk M, Birant A, Kurtar Mansıroglu A, Akturk IF, Karakurt H, Yalcin AA, Uzun F, Somuncu MU, Yildirim A.
    Cardiol J; 2015 Jun; 22(1):87-93. PubMed ID: 24846511
    [Abstract] [Full Text] [Related]

  • 3. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S, Cetin M, Ciçekçioğlu H, Uçar O, Çetin ZG, Ozuğuz U, Bakır F, Berker D, Güler S.
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [Abstract] [Full Text] [Related]

  • 4. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
    Duman D, Palit F, Simsek E, Bilgehan K, Sacide A.
    Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
    [Abstract] [Full Text] [Related]

  • 5. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
    Lunghetti S, Palmerini E, Urselli R, Maffei S, Guarino E, Focardi M, Mondillo S, Favilli R.
    Cardiol J; 2011 Oct; 18(5):532-7. PubMed ID: 21947989
    [Abstract] [Full Text] [Related]

  • 6. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G, Kremastinos DT.
    Int J Cardiol; 2010 Feb 18; 139(1):75-9. PubMed ID: 18973957
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS, Huang SJ, Nalos M, Ting I.
    J Cardiovasc Pharmacol; 2005 Dec 18; 46(6):830-5. PubMed ID: 16306809
    [Abstract] [Full Text] [Related]

  • 11. Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
    Büyüklü M, Kürüm AT, Tatlý E, Set T.
    Arq Bras Cardiol; 2012 Jul 18; 99(1):659-64. PubMed ID: 22735864
    [Abstract] [Full Text] [Related]

  • 12. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT.
    Heart; 2006 Dec 18; 92(12):1768-72. PubMed ID: 17105880
    [Abstract] [Full Text] [Related]

  • 13. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ, Sun ZX, Su CY, Tan H, Zhong X, Hu B, Zhou Y, Shang DY.
    Cardiovasc Ther; 2013 Apr 18; 31(2):108-14. PubMed ID: 23490237
    [Abstract] [Full Text] [Related]

  • 14. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.
    Am J Cardiol; 2006 Jul 01; 98(1):102-6. PubMed ID: 16784930
    [Abstract] [Full Text] [Related]

  • 15. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikström G.
    Eur J Heart Fail; 2010 Apr 01; 12(4):404-10. PubMed ID: 20335355
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G, Kremastinos DT.
    Am J Cardiol; 2008 Nov 01; 102(9):1225-9. PubMed ID: 18940297
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.